Open an account

Response Genetics

RGDXQ · OTC

$0.00−$0.00 (−50.00%)TodayMarket closed ·
No price history for this range.

About RGDXQ

Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer. The company is headquartered in Los Angeles, California and currently employs 96 full-time employees. The company went IPO on 2007-06-05. The firm is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The firm's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The firm is engaged in selling ResponseDX diagnostic testing products. The firm provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.

Employees
98
Headquarters
Los Angeles, California
Listed
Jun 5, 2007
Sector
Health Care
Industry
Life Sciences Tools & Services

RGDXQ key statistics

Market cap
39
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
2.00K
Volume
422
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.00
52 Week low
$0.00

Response Genetics (RGDXQ) at a glance

As of Aug 12, 2026, Response Genetics (RGDXQ) shares are priced at $0.00, giving the company a market cap of 39 and a price-to-earnings ratio of 0.00.

Volume so far is 422 shares, below the average of 2.00K shares a day.

Over the past year Response Genetics has ranged from $0.00 to $0.00, and now sits 0% of the way up that range.

Response Genetics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q1 FY14 it reported -$0.09 per share against an estimate of -$0.0515.

RGDXQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 31.1% on average.

  1. Q2 FY12: reported -$0.11 per share against an estimate of -$0.1236
  2. Q3 FY12: reported -$0.05 per share against an estimate of -$0.0721
  3. Q4 FY12: reported -$0.01 per share against an estimate of -$0.0618
  4. Q1 FY13: reported -$0.03 per share against an estimate of -$0.0412
  5. Q2 FY13: reported -$0.04 per share against an estimate of -$0.0412
  6. Q3 FY13: reported -$0.08 per share against an estimate of -$0.0721
  7. Q4 FY13: reported -$0.09 per share against an estimate of -$0.0721
  8. Q1 FY14: reported -$0.09 per share against an estimate of -$0.0515

Similar companies

Companies in the same industry as Response Genetics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.